A Phase-I, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a dual PI3K delta/gamma inhibitor, in patients with Relapsed or Refractory Hematologic Malignancies
Latest Information Update: 25 May 2021
At a glance
- Drugs Tenalisib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Haematological malignancies; Hodgkin's disease; Lymphoproliferative disorders; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Rhizen Pharmaceuticals
- 04 Dec 2018 Results of the pooled safety analysis of Tenalisib from NCT02017613 and NCT02567656 (n=93) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 06 Dec 2016 Final analysis results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 23 Jun 2016 Status changed from active, no longer recruiting to completed.